For security reasons, you will be logged out in 4 minutes
0
Cannot be added! Your basket contains a blocked quote and must be finalised before you can order other items. Add to basket... Item added to basket

 

The BIORCELL3D® consortium brings together researchers in Biology and Pharmaco-chemistry from the IMoST research team (UMR INSERM-UCA 1240) and specialists from the Biotechnology industry from BIOPASS and BIOMARQUEURS (Clermont-Ferrand - 63).

Together, they develop and sell innovative preclinical biotechnology tools applied to Health and the Environment, such as :

 


Artificial Tumours® (3D cultures) for new cancer drug screening. These preclinical models are derived from well-known tumor cell lines widely used by researchers and faithfully reproduce avascular micro-tumors. They are available as a service or as ready-to-use kits (Opti3D® kits).

 

 

Serum-free and chemically defined culture media as alternatives to calf serum, allowing 2D and 3D cell culture of a wide range of cell types (healthy and tumorous), as well as short-term preservation of cell samples without freezing (OptiPASS® media range).

 

 

Fluorescent reagents capable of measuring the level of resistance of tumor cells following anticancer treatments in a rapid and dynamic manner (Patent registered LightSpot® by UCA-BIOMARQUEURS).     
 

 

Services: custom development of new 3D models, screening of molecules (drug screening), or efficacy tests using artificial tumors.

 

 

See all Biorcell products

 

 

PRODUCTS
  
 

Artificial Tumour Kits® (ATK)

 

 

Artificial Tumor Kits® in ready-to-use microplates for in vitro testing

Artificial Tumors® (3D cultures) from tumor cell lines widely used in oncology, and in particular derived from aggressive triple-negative breast cancers.

  • Artificial tumors more closely mimic the microenvironment of avascular tumors in vivo than 2D cultures.
  • These models are increasingly becoming part of the drug development processes.


Discover

 

Serum-free culture media

 

Complete, ready-to-use serum-free cell culture media

OptiPASS® serum-free and chemically defined media can be used for the culture of tumorous or healthy cells, in monolayer (2D culture) and 3D culture (spheroids, organoids) of a wide range of tumour types of interest in preclinical research.

 

 

2D Culture (tumorous and healthy cells) and Bioproduction

 

For 2D culture, the OptiPASS® medium allows :

  • cell proliferation and viability similar to serum medium culture (reference)
  • preservation of the cell phenotype

 

Non-exhaustive list of tumour and healthy lines validated in 2D culture (OPTI03):

  • healthy tissue - allowing bioproduction: VERO E6
  • healthy tissue - MCF-10A
  • breast cancer: MDA-MB 231 and CAL51
  • prostate cancer: PC3
  • lung cancer: NCI H1975
  • ovarian cancer: SK-OV-3
  • melanoma: A375

 

(Requires prior coating of culture plates, please refer to the technical department for further information and support)7

 

 

3D culture ( tumorous and healthy cells)

 

Benefits : 

  • maintenance/increase in the rate of proliferation/growth
  • maintenance of metabolic gradients within cultures (live cells/dead cells)
  • reproducibility of production in terms of size and proliferation/growth

 

List of tumour lines validated in 3D culture:

  • breast cancer: MDA-MB-231, SUM1315 and BT 474
  • prostate cancer: PC-3
  • lung cancer: NCI-H1975
  • ovarian cancer: SK-OV-3, OVCAR-3
  • melanoma: A375

 

Oncology-preservation

Once produced, the 3D cultures can be stored for several days in OptiPASS® (OPTI05), under anoxic conditions and at 4°C before being analyzed. 
Examples of tumor lines validated with this method: breast: MDA-MB-231, SUM1315.


Discover

 

 

Fluorescent Biotracers

 

Innovation improving the detection, localization, and quantification of Multidrug Resistance proteins in all cellular samples.

Applications:

  • better control of efflux: kidney, liver, blood-brain barrier, placental barrier;
  • evaluate cellular resistance to different molecules and exogenous agents (active ingredients, pollutants, anti-infectious agents).

 

Aims:

  • optimizing cancer treatment by quantifying chemoresistance of certain drugs;
  • improving efflux modulation.

 

Available for different excitation/emission wavelengths.

 

 

Service provision   
  

 

Customized 3D cell culture models

 

Development of new 3D tumor cell models on demand.

  • Analysis of requirements according to the cell type and choice of the most suitable 3D technique
  • Identification of optimal growing conditions
    • Choice of culture device (specific microplates);
    • Cell concentrations, type, and matrix concentration (if applicable);
    • Objective: reproducibility and stability of models (coefficient of variation in size < 10 %).
  • Characterisation of models
    • Growth profile;
    • Metabolic profile;
    • Maximum cultivation time;
    • Topology (Scanning Electron Microscopy SEM);
    • Ultrastructure (Transmission Electron Microscopy TEM);
    • Expression profile of proteins of interest.
  • Deliverables
    • 3D cell culture protocol adapted to your cell type;
    • Ready-to-use kits containing your 3D models (if development possible in OptiPASS®).
  • Estimated development time: between 2 and 3 months depending on the models

 

Screening / Customised screening

 

Development of new 3D tumour cell models on demand.

  • Requirement analysis
  • Choice of tumor models
  • Development of adapted tests (when appropriate)
  • Identification of treatment modalities / duration / type of exposure / doses
  • Reception and preparation of test molecules
  • Carrying out the tests
  • Identification of deliverables (non-exhaustive)
    • Viability %, Growth inhibition, IC50;
    • Impact on the cell cycle;
    • Tagging and quantification of targets of interest;
    • Clonogenic tests, etc.
  • Secure archiving of raw and analyzed data
  • Deliverables: full analysis reports
  • Deliverables: full analysis reports

 

 

 

Documentation and videos

Presentation of the screening service      

 

For more details on Biocell3D® products and services, brochures are available for download.

LightSpot®Artificial Tumour Kits® and serum-free culture media      


 

Romain GUEGAN 
Responsable France de la culture cellulaire et des projets de thérapies